Lantern Pharma Reports Q1 2026 Results, Cuts R&D Spending 47% and Advances AI Commercialization with Zeta.ai Launch

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, reported first-quarter 2026 operational highlights and financial results, demonstrating significant progress in both its clinical pipeline and artificial intelligence commercialization strategy. The company achieved a 47% year-over-year reduction in research and development spending while advancing multiple clinical programs through key regulatory milestones.

Among the most notable achievements was a successful U.S. Food and Drug Administration (FDA) Type C meeting outcome for the Phase 2 HARMONIC trial of LP-300, a cisplatin/ethacraplatin analog being evaluated in never-smoker patients with relapsed advanced lung adenocarcinoma following tyrosine kinase inhibitor (TKI) treatment. Additionally, Lantern's wholly owned subsidiary, Starlight Therapeutics, received IND clearance for its first pediatric central nervous system (CNS) cancer program, which utilizes LP-184, an acylfulvene compound. LP-184 is also being developed for other indications, including hematologic and solid tumors via LP-284, a TC-NER targeting compound.

Financially, Lantern reported that recent financing of up to $9.25 million extends its operating runway into the first quarter of 2027. The company also outlined plans to separate its AI assets into an independent entity, a move that could unlock value for shareholders. Central to this strategy is withZeta.ai, Lantern's multi-agentic AI drug development platform, which was launched as a commercially available subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, leveraging its proprietary RADR platform and AI capabilities.

Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's recent developments underscore its commitment to transforming cancer therapy development through artificial intelligence and machine learning. For more details, the full press release is available at https://ibn.fm/R1C54.

Investors and stakeholders can find the latest news and updates on Lantern Pharma at the company's newsroom: https://ibn.fm/LTRN.